Water Logos

lp-banner-analysis-of-drug-pill.jpg

Bioanalysis Needs of Today and Tomorrow: A 60-Second Q&A with Synexa Life Science’s Paul Holme

DMPK workflows, not workarounds.

See how Synexa Life Sciences (formerly Alderley Analytical) retooled bioanalysis — adding the ACQUITY™ Premier UPLC™ System, the Xevo™ TQ Absolute Mass Spectrometer, a lab information management system (LIMS), and robotics — to deliver robust, scalable assays to support complex, large cohort studies. Get Paul Holme’s 60-second take on what’s coming next (including the evolving therapeutic landscape and analytical toolset) and why sustainability matters.

“We are lucky that our technology suppliers understand the challenges and provide an array of solutions to help.” – Paul Holme, Synexa Life Sciences [formerly Alderley Analytical]


Fill out the form to access the Q&A and explore how:

  • Increased complexity of analytes, coupled with increased cohort sizes, requires modernization of the complete bioanalytical workflow
  • Maximizing operational efficiency and resource utilization demand robust, scalable LC-MS/MS platforms that minimize time consuming passivation or downtime
  • The Xevo TQ Absolute Mass Spectrometer and the ACQUITY Premier UPLC System combine with secure informatics workflows, including LIMS/eNotebooks
  • Upskilling & regular training of staff helps productivity and keeps teams agile


ACQUITY, UPLC, and Xevo are trademarks of Waters Technologies Corporations.